Wassilis C. Bruins

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 12 publications

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Immune signatures in older patients with newly diagnosed multiple myeloma are associated with survival outcomes of first-line therapy irrespective of frailty levels.

Journal: HemaSphere
Published: March 17, 2025

A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.

A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy.

Journal: Blood
Published: January 27, 2025

Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma.

Monocyte-mediated metabolic rewiring via CD31-CD38 interactions promotes growth and drug-resistance in multiple myeloma.

Journal: HemaSphere
Published: October 11, 2024

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy.

Journal: Blood
Published: August 08, 2024

Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma.

Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myeloma.

Journal: Journal for immunotherapy of cancer
Published: July 07, 2024

Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma.

Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma.

Journal: HemaSphere
Published: May 23, 2024

Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.

Response to DA-EPOCH-R is associated with activation of 'fitter' cytotoxic T cells in patients with newly diagnosed double and triple hit high-grade B-cell lymphoma.

Journal: Haematologica
Published: February 11, 2024

T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.

T-Cell Characteristics Impact Response and Resistance to T-Cell-Redirecting Bispecific Antibodies in Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 30, 2023

Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.

Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS.

Journal: Blood advances
Published: September 14, 2023

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

NK Cell Phenotype Is Associated With Response and Resistance to Daratumumab in Relapsed/Refractory Multiple Myeloma.

Journal: HemaSphere
Published: November 07, 2022

Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma.

Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma.

Journal: JCO precision oncology
Published: February 21, 2020

Targeted Therapy With Immunoconjugates for Multiple Myeloma.

Targeted Therapy With Immunoconjugates for Multiple Myeloma.

Journal: Frontiers in immunology
Published: January 30, 2020
Showing 1-12 of 12

Last Updated: 09/26/2026